Kumar S. Nomogram-based strategy to predict relapse-free survival in patients with gastrointestinal stromal tumor using inflammatory indicators. World J Gastrointest Oncol 2025; 17(5): 103127 [DOI: 10.4251/wjgo.v17.i5.103127]
Corresponding Author of This Article
Shashank Kumar, PhD, Assistant Professor, Department of Biochemistry, Central University of Punjab, VPO Ghudda Central University of Punjab Lab no 520, Bathinda 151401, Punjab, India. shashankbiochemau@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. May 15, 2025; 17(5): 103127 Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.103127
Nomogram-based strategy to predict relapse-free survival in patients with gastrointestinal stromal tumor using inflammatory indicators
Shashank Kumar
Shashank Kumar, Department of Biochemistry, Central University of Punjab, Bathinda 151401, Punjab, India
Author contributions: Kumar S conceived the study and wrote, reviewed, and edited the manuscript.
Conflict-of-interest statement: Dr. Kumar has no conflicts of interests to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shashank Kumar, PhD, Assistant Professor, Department of Biochemistry, Central University of Punjab, VPO Ghudda Central University of Punjab Lab no 520, Bathinda 151401, Punjab, India. shashankbiochemau@gmail.com
Received: November 10, 2024 Revised: January 20, 2025 Accepted: February 5, 2025 Published online: May 15, 2025 Processing time: 186 Days and 21.2 Hours
Abstract
Zhao et al’s investigation on the assessment of inflammatory markers prognostic value for relapse-free survival in patients with gastrointestinal stromal tumor (GIST) using a nomogram-based approach is a scientific approach. This study explored the potential of an inflammatory marker-based nomograph model, highlighting the relapse-free survival-associated risk factors prognostic potential in patients with GIST. The author assessed 124 samples from patients with GIST to find an association between inflammatory markers and tumor size in a retrospective study using multivariate regression analysis. Further, a nomogram model was developed to identify the independent risk factors for the prognosis. GIST clinical treatment can use preoperative monocyte/lymphocyte ratio and platelet/lymphocyte ratio for relapse-free survival prognosis as independent factors.
Core Tip: This retrospective study evaluated inflammatory indicators' predictive significance for relapse-free survival in patients with gastrointestinal stromal tumor (GIST) utilizing a nomogram-based technique. The author tried to associate test preoperative inflammatory indicators with recurrence-free survival. The study created a GIST prognostic nomogram using inflammatory markers, but the limitation(s) and its possible effect on the outcome of GIST prognosis were not discussed. Inclusion and exclusion criteria should be broad enough to minimize the false-positive effects of immune marker levels in test samples. Normalization of inflammatory markers in response to different chemotherapeutic drug(s) is important for obtaining a stable prognostic outcome in GIST.
